glutathione mutations in sclc patients Increased antioxidative defense and reduced advanced glycation end-product formation by metabolic adaptation non-small-cell-lung-cancer Antibody-drug conjugates: A new twist
Antibody drug conjugates: A new twist to overcome EGFR TKIs resistance in non small cell lung cancer ScienceDirect In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer Science Advances Immunotherapy in small cell lung cancer: from molecular promises to clinical challenges Journal for ImmunoTherapy of Cancer Inhibiting the system xC glutathione axis selectively targets cancers with mutant p53 accumulation Nature Communications Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR Mutant Lung Cancer
Pay in 4 interest-free payments of $7.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




